If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...

Genethon, a leading laboratory in gene therapy for rare diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with AskBio, a gene therapy company wholly owned ...

Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...

About the FALCON Trial FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been ...

Social determinants of health (SDOH) were found to be associated with increased risk of heart failure (HF) and ventricular arrhythmias (VA) in patients with hypertrophic cardiomyopathy (HCM), ...

A year-long experiment found that even low doses of aspartame—well below current safety limits—may disrupt brain energy use and heart function, prompting experts to call for a re-evaluation of its ...

A recent study published in Engineering has shed new light on the role of the protein NSUN2 in the development of cardiac hypertrophy and heart failure. The research, conducted by a team from Harbin ...

A recent study published in Engineering has shed new light on the role of the protein NSUN2 in the development of cardiac hypertrophy and heart failure. The research, conducted by a team from Harbin ...

A recent study published in the January 2026 edition of Biomedicine & Pharmacotherapy determined that the popular artificial sweetener aspartame may harm the heart and brain. When administering to ...

Heart disease is the top cause of death in the United States, resulting in one in three deaths in 2023. In addition to being such a vital organ, the adult heart, unlike other parts of the body, cannot ...